TMCnet News
OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi®
NANTES, France, July 05, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) today announces that the Company received a grant through the Eurostars European Programme to fund a project entitled: “Treatment Response Monitoring for Cancer Immunotherapies Using Immune Repertoire Analysis” (Immunomonitor). The project, to be conducted by a European consortium of five partners, will clinically validate and analyse a platform of immune repertoire sequencing-data (T-cell receptors) with the goal of generating an immune fingerprint specific to Tedopi®. “We warmly thank Bpifrance for supporting us with this European grant and are pleased to collaborate with such a respected group of partners,” said Alexis Peyroles, CEO of OSE Immunotherapeutics. “We look forward to validating an immune algorithm specific to Tedopi® and establishing precision medicine targeting for our product.” The €435,000 grant will support translational research, which will be conducted in conjunction with the Phase 2 clinical trial for Tedopi® in pancreatic cancer, combined with a PD-1 checkpoint inhibitor. Researchers will use bioinformatic algorithms of T-cell receptors to generate an immune fingerprint specific to Tedopi®. The Phase 2 study, sponsored by the oncology cooperative group GERCOR as part of PRODIGE intergroup, is expected to initiate later in 2018. The European consortium of the five collaborating partners includes: Enpicom (Netherlands), a bioinformatics company; Biomax Informatics (Germany), a bioinformatics company; Ultimovacs (Norwegian), a pharma company developing T immunotherapies specific to cancer (specifically htert peptides); the University Medical Center Hamburg-Eppendorf (Germany); and OSE Immunotherapeutics (France). The consortium is being led by Enpicom. ABOUT EUROSTARS ABOUT OSE Immunotherapeutics Click and follow us on Twitter and Linkedln Contacts
Forward-looking statements These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. |